Advertisement

Neuroblastoma pp 375-383 | Cite as

Palliative Care

  • Alessandro InserraEmail author
  • Alessandro Crocoli
Chapter

Abstract

Despite the outstanding advancement in multimodal therapies over the last decades, neuroblastoma still represents challenge for physicians for significant mortality rate especially for high-risk patients. In this respect, palliative care for terminally ill children plays different important roles as impossibility to cure does not mean absence of treatments. Control of disease and management of symptoms are the cornerstones of end-of-life therapies, in order to guarantee high-quality life for both as long and as comfortably as possible.

Keywords

Neuroblastoma Palliative care Palliation Chemotherapy Surgery Radiotherapy End of life treatments 

References

  1. 1.
    Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28(15):2625–34.CrossRefGoogle Scholar
  2. 2.
    Mak KS, Lee SW, Balboni TA, Marcus KJ. Clinical outcomes and toxicity following palliative radiotherapy for childhood cancers. Pediatr Blood Cancer. 2017;65(1)  https://doi.org/10.1002/pbc.26764.CrossRefGoogle Scholar
  3. 3.
    Farber S. Chemotherapeutic studies of tumors, including leukemia, in children. Am J Dis Child. 1950;79(5):961–2.PubMedGoogle Scholar
  4. 4.
    Noone AM, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiol Biomark Prev. 2017;26(4):632–41.CrossRefGoogle Scholar
  5. 5.
    Hooper WC, Holman RC, Strine TW, Chorba TL. Hodgkin disease mortality in the United States: 1979–1988. Cancer. 1992;70(5):1166–71.CrossRefGoogle Scholar
  6. 6.
    Karalexi MA, Georgakis MK, Dessypris N, Ryzhov A, Zborovskaya A, Dimitrova N, et al. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. Hematol Oncol. 2017;35(4):608–18.CrossRefGoogle Scholar
  7. 7.
    Farber S. Chemotherapy in the treatment of leukemia and Wilms’ tumor. JAMA. 1966;198(8):826–36.CrossRefGoogle Scholar
  8. 8.
    Pritchard-Jones K, Moroz V, Vujanic G, Powis M, Walker J, Messahel B, et al. Treatment and outcome of Wilms’ patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol. 2012;23(9):2457–63.CrossRefGoogle Scholar
  9. 9.
    Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining childhood and adolescent cancer mortality. Cancer. 2014;120(16):2497–506.CrossRefGoogle Scholar
  10. 10.
    Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.CrossRefGoogle Scholar
  11. 11.
    Kowalczyk JR, Samardakiewicz M, Pritchard-Jones K, Ladenstein R, Essiaf S, Fitzgerald E, et al. European survey on standards of care in paediatric oncology centres. Eur J Cancer. 2016;61:11–9.CrossRefGoogle Scholar
  12. 12.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRefGoogle Scholar
  13. 13.
    Humphrey L, Kang TI. Palliative care in pediatric patients with hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2015;2015:490–5.CrossRefGoogle Scholar
  14. 14.
    Feudtner C, Friebert S, Jewell J, Friebert S, Carter B, Feudtner C, Hood M, Imaizumi S, Komatz K, SECTION ON HOSPICE AND PALLIATIVE MEDICINE AND COMMITTEE ON HOSPITAL CARE. Pediatric palliative care and hospice care commitments, guidelines, and recommendations. Pediatrics. 2013;132(5):966–72.  https://doi.org/10.1542/peds.2013-2731.
  15. 15.
    American Academy of Pediatrics. Committee on Bioethics and Committee on Hospital Care. Palliative care for children. Pediatrics. 2000;106(2 Pt 1):351–7.CrossRefGoogle Scholar
  16. 16.
    Ahmed AA, Zhang L, Reddivalla N, Hetherington M. Neuroblastoma in children: update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol. 2017;34(3):165–85.CrossRefGoogle Scholar
  17. 17.
    Evans AE, Albo V, D’Angio GJ, Finklestein JZ, Leiken S, Santulli T, et al. Factors influencing survival of children with nonmetastatic neuroblastoma. Cancer. 1976;38(2):661–6.CrossRefGoogle Scholar
  18. 18.
    Weaver MS, Heinze KE, Bell CJ, Wiener L, Garee AM, Kelly KP, et al. Establishing psychosocial palliative care standards for children and adolescents with cancer and their families: an integrative review. Palliat Med. 2016;30(3):212–23.CrossRefGoogle Scholar
  19. 19.
    Himelstein BP, Hilden JM, Boldt AM, Weissman D. Pediatric palliative care. N Engl J Med. 2004;350(17):1752–62.CrossRefGoogle Scholar
  20. 20.
    Inserra A, Narciso A, Paolantonio G, Messina R, Crocoli A. Palliative care and pediatric surgical oncology. Semin Pediatr Surg. 2016;25(5):323–32.CrossRefGoogle Scholar
  21. 21.
    Kushner BH, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999;17(10):3221–5.CrossRefGoogle Scholar
  22. 22.
    Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, Oberlin O, et al. Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol. 2011;4(4):203–11.CrossRefGoogle Scholar
  23. 23.
    Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, et al. SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015;62(8):1305–16.CrossRefGoogle Scholar
  24. 24.
    Kushner BH, Kramer K, Modak S, Cheung NK. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer. 2005;103(4):858–62.CrossRefGoogle Scholar
  25. 25.
    Osone S, Hosoi H, Tsuchiya K, Misawa A, Iehara T, Sugimoto T. Low-dose protracted irinotecan as a palliative chemotherapy for advanced neuroblastoma. J Pediatr Hematol Oncol. 2008;30(11):853–6.CrossRefGoogle Scholar
  26. 26.
    Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm. 2005;20(2):195–9.CrossRefGoogle Scholar
  27. 27.
    Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2011;29(33):4351–7.CrossRefGoogle Scholar
  28. 28.
    DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, et al. Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer. 2015;112(4):644–9.CrossRefGoogle Scholar
  29. 29.
    Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M, et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol. 2003;25(10):769–73.CrossRefGoogle Scholar
  30. 30.
    Weyl Ben-Arush M, Ben Barak A, Bar-Deroma R, Ash S, Goldstein G, Golan H, Houri H, Waldman D, Nevo N, Bar Shalom R, Berniger A, Nevelsky A, Toren A, Yaniv I, Kuten A. Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. Israel Med Assoc J. 2013;15(1):31–4.Google Scholar
  31. 31.
    Rahn DA 3rd, Mundt AJ, Murphy JD, Schiff D, Adams J, Murphy KT. Clinical outcomes of palliative radiation therapy for children. Pract Radiat Oncol. 2015;5(3):183–7.CrossRefGoogle Scholar
  32. 32.
    Varma S, Friedman DL, Stavas MJ. The role of radiation therapy in palliative care of children with advanced cancer: clinical outcomes and patterns of care. Pediatr Blood Cancer. 2017;64(5)  https://doi.org/10.1002/pbc.26359.CrossRefGoogle Scholar
  33. 33.
    Vern-gross T. Pediatric palliative radiation oncology. In: Lutz S, Chow E, Hoskin P, editors. Radiation oncology in palliative cancer care. Chichester, UK: John Wiley & Sons, Ltd; 2017. p. 220–37.Google Scholar
  34. 34.
    Paulino AC. Palliative radiotherapy in children with neuroblastoma. Pediatr Hematol Oncol. 2003;20(2):111–7.CrossRefGoogle Scholar
  35. 35.
    Deutsch M, Tersak JM. Radiotherapy for symptomatic metastases to bone in children. Am J Clin Oncol. 2017;27(2):128–31.CrossRefGoogle Scholar
  36. 36.
    Caussa L, Hijal T, Michon J, Helfre S. Role of palliative radiotherapy in the management of metastatic pediatric neuroblastoma: a retrospective single-institution study. Int J Radiat Oncol Biol Phys. 2011;79(1):214–9.CrossRefGoogle Scholar
  37. 37.
    Bhasker S, Bajpai V, Turaka A. Palliative radiotherapy in paediatric malignancies. Singap Med J. 2008;49(12):998–1001.Google Scholar
  38. 38.
    Aguayo P, Ho B, Fraser JD, Gamis A, St Peter SD, Snyder CL. Bowel obstruction after treatment of intra-abdominal tumors. Eur J Pediatr Surg. 2010;20(4):234–6.CrossRefGoogle Scholar
  39. 39.
    Parbhoo DM, Tiedemann K, Catto-Smith AG. Clinical outcome after percutaneous endoscopic gastrostomy in children with malignancies. Pediatr Blood Cancer. 2011;56(7):1146–8.CrossRefGoogle Scholar
  40. 40.
    Buderus S, Sonderkötter H, Fleischhack G, Lentze MJ. Diagnostic and therapeutic endoscopy in children and adolescents with cancer. Pediatr Hematol Oncol. 2012;29(5):450–60.CrossRefGoogle Scholar
  41. 41.
    Sacks N, Hwang WT, Lange BJ, Tan KS, Sandler ES, Rogers PC, et al. Proactive enteral tube feeding in pediatric patients undergoing chemotherapy. Pediatr Blood Cancer. 2014;61(2):281–5.CrossRefGoogle Scholar
  42. 42.
    Huhmann MB, August DA. Nutrition support in surgical oncology. Nutr Clin Pract. 2009;24(4):520–6.CrossRefGoogle Scholar
  43. 43.
    Crocoli A, Tornesello A, Pittiruti M, Barone A, Muggeo P, Inserra A, et al. Central venous access devices in pediatric malignancies: a position paper of Italian Association of Pediatric Hematology and Oncology. J Vasc Access. 2015;16(2):130–6.CrossRefGoogle Scholar
  44. 44.
    Lambert SM. Transitional care in pediatric urology. Semin Pediatr Surg. 2015;24(2):73–8.CrossRefGoogle Scholar
  45. 45.
    van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–49.CrossRefGoogle Scholar
  46. 46.
    Wolfe J, Grier HE, Klar N, Levin SB, Ellenbogen JM, Salem-Schatz S, et al. Symptoms and suffering at the end of life in children with cancer. N Engl J Med. 2000;342(5):326–33.CrossRefGoogle Scholar
  47. 47.
    Theunissen JM, Hoogerbrugge PM, van Achterberg T, Prins JB, Vernooij-Dassen MJ, van den Ende CH. Symptoms in the palliative phase of children with cancer. Pediatr Blood Cancer. 2007;49(2):160–5.CrossRefGoogle Scholar
  48. 48.
    Tobias JD. Applications of intrathecal catheters in children. Paediatr Anaesth. 2000;10(4):367–75.CrossRefGoogle Scholar
  49. 49.
    Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain. 2003;4(8):441–7.CrossRefGoogle Scholar
  50. 50.
    Deer TR, Levy R, Prager J, Buchser E, Burton A, Caraway D, et al. Polyanalgesic consensus conference—2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation. 2012;15(5):467–82; discussion 82.CrossRefGoogle Scholar
  51. 51.
    Bond MC, Pritchard S. Understanding clinical trials in childhood cancer. Paediatr Child Health. 2006;11:148–50.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol. 2005;23(18):4039–47.CrossRefGoogle Scholar
  53. 53.
    Amoroso L, Haupt R, Garaventa A, Ponzoni M. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma. Expert Opin Investig Drugs. 2017;26:1281–93.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Operative Unit of General and Thoracic SurgeryBambino Gesù Children’s Hospital IRCCSRomeItaly

Personalised recommendations